anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Water-in-volatile silicone emulsifier concentrates containing 2 to 30 wt. % water in the internal phase, 40 to 90 wt. % of a volatile cyclic silicone liquid such as the octamethylsiloxane cyclic tetramer, decamethylsiloxane cyclic pentamer or the dodecamethylsiloxane cyclic hexamer and 5 to 40 wt. % of a polyoxyalkylene substituted silicone containing per molecule 5 to 100 dialkylsiloxy units, two trialkylsiloxy end blocking units and 1 to 16 polyoxyalkylene substituted alkylsiloxy units of the average formula:   <IMAGE>   in which R is an alkyl group having 1 to 4 carbon atoms and R can individually be the same or different, wherein R DEG  is a terminal group selected from the class consisting of hydrogen, alkyl, aryl, aralkyl and acyl radicals, n is an integer of 2 to 8, a is a number of 5 to 20 and b is 2 or 3. Said emulsifier concentrates are highly useful in preparing water-in-silicone personal-care emulsions by simply mixing same with desired personal-care components soluble therein followed by mixing with water in which water soluble personal-care components may be mixed. The personal-care components include the well known materials such as emollients, film formers, sun screen agents, moisture barriers, anti-perspirants and the like. Processes are also described for preparing the water-in-silicone emulsifier concentrates and emulsions mentioned above.
305,475. I. G. Farbenindustrie Akt.- Ges. Feb. 4, 1928, [Convention date]. Medicines for internal use.-Active substances are obtained from the fresh or dried whole hypophysis, without previous separation of the two lobes, by hydrolysis by means of an alkali or an acid, conditions as to time and temperature being controlled so as to avoid decomposition of the active substances. The process may be carried out in steps so that the various active substances are separately obtained. Albumin degradation products are precipitated by adjusting the hydrogen ion concentration of the ,solution. A water-soluble organic solvent may be added to the solution to precipitate further impurities. According to examples, (1) fresh whole hypophysis is ground in water, hydrochloric acid gas is passed for 30 minutes at 15‹ C. and the mass centrifuged, these operations are repeated, and the combined liquids are neutralized with strong caustic soda solution and centrifuged and, if desired, further purified by addition of acetone; (2) dry powdered whole hypophysis is treated with N/2 caustic soda for 20 minutes at 35‹-40‹ C., centrifuged to obtain a liquid containing the active substance of the posterior lobe, and the remaining solid is repeatedly treated with N- caustic soda each time for 20 minutes at 25‹ C. to obtain a second liquid containing the active substance of the anterior lobe, the two liquids. separately or mixed together, being neutralized with 2-N-hydrochloric acid to precipitate ballast substances; (3) a mixture of the anterior and posterior lobes of the hypophysis is extracted with 3 per cent sodium sulphide solution for 20 minutes at 15‹ C., the extract is centrifuged and neutralized, these steps are repeated, the combined liquids are adjusted to PH5 to precipitate albuminous substances, and hydrogen sulphide liberated is eliminated by any usual process not involving heating. Various concentrations of caustic soda, and of hydrochloric acid, are referred to as hydrolysing agents. The Specification as open to inspection under Sect. 91 (3) (a) refers also to treatment of the separated parts of the gland in the manner above set forth and to the use of sulphuric acid as a hydrolysing agent. This subject-matter does not appear in the Specification as accepted.
FIELD: medicine, virology. SUBSTANCE: the suggested preparation contains hyaluronic acid, trimecaine, glycerol and polyethylenoxide. Preparation is obtained either as a gel or an ointment. A kind of medicinal form depends upon molecular weight of polyethylenoxide used. EFFECT: increased therapeutic and antiherpetic activity, improved transdermal, wound-healing and antiviral actions. 1 cl, 1 tbl, 5 ex
Alzheimer's Disease (AD) is a progressive neurodegenerative disease and the main cause of dementia. Its etiology remains largely unclear, though genetic and environmental factors appear to confer susceptibility to AD development. This study assessed the role of ATP-binding Cassette A Subfamily 7 (ABCA7) genetic polymorphisms, as ongoing research suggests they have a role in the development of AD. We conducted a PubMed, Google Scholar, and Scopus search to identify and assess all AD studies examining ABCA7 variants in different populations and ethnicities. The last search was conducted on February 8, 2023. Inclusion and exclusion criteria were applied and only the studies that met the inclusion criteria were included in this review. Seventeen studies were finally included. According to the results, ABCA7 variants infer different risks for AD among populations with different ancestries. African American populations show a higher risk for AD, carrying the five novel variants rs115550680, rs142076058, rs10405305, rs3764647, and rs567222111. Asian populations also have an increased risk for AD, harboring three variants. ABCA7 genetic variability contributes to AD development and shows racial disparities. African American and Asian populations seem to be at greater risk of developing AD. These results may assist future research efforts for the early and accurate diagnosis of AD. Moreover, further exploration of the mechanisms of ABCA7 in the context of AD could identify potential therapeutic targets.
Oral lichen ruber (OLR) in the diabetes mellitus patients has more aggressive clinical course in the form of atrophic-erosive and ulcerative lesions showing an increased tendency to malignant transformation. OLR epithelial cells show anomalies in both enzymatic activity and carbohydrate metabolism, which may be related to hormones regulating carbohydrate, insulin and insulin-like Growth Factors 1 and 2 (IGF-1 and IGF-2) metabolism. The role of insulin-like growth factors (IGFs) is of great importance in normal growth and cell development (cell proliferation, differentiation and apoptosis), and is involved in different aspects of cell transformation in malignant phenotype. A change in the expression of IGF1, IGF2 and IGF2R proteins is described in several types of malignant tumors including oral cancer. However, data on their role in the development of malignant lesions of the oral cavity are scarce, and the results are inconsistent. Our hypothesis is that patients with diabetes mellitus and oral lichen ruber lesions will have a disturbance of insulin-like growth factors 1 and 2 and hence a greater risk of malignant transformation, compared to patients with oral lichen ruber without diabetes and healthy patients without alterations in the oral mucosa.
Ankylosing spondylitis (AS), a subset of axial spondyloarthritis (axSpA), is a chronic inflammatory disorder characterized by inflammatory back pain and predominant involvement of sacroiliac joints and spine, leading to bony fusion of vertebrae and eventually disability in some patients. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recognized as a first-line therapy for AS, but the overall response rates to NSAIDs are considerably unsatisfactory. With the advent of biologics, the outcomes of AS patients have been greatly improved. Biologics including tumor necrosis factor α (TNFα) inhibitors (TNFi) have been included in many recommendations for the treatment of AS. Etanercept, a recombinant human TNFα receptor, is capable of binding to TNFα and blocking its biological activities. It is effective in relieving symptoms, improving physical function, and reducing disease activity in patients with AS, and generally no severe adverse effects have been reported. However, the high expense of biologics restricts their long-term use, which urges a viable strategy to reduce the dosage of biologics while maintaining an optimal therapeutic efficacy. To investigate the stepwise tapering and discontinuation of TNFi based on disease activity in patients with AS, a 48-week, prospective, randomized, multicentric study was conducted. An etanercept biosimilar, rhTNFR:Fc (recombinant TNF receptor: Fc fusion protein, Yisaipu), which is one of the most widely used biosimilars in China, was used in this study.
Osteoporosis (OP) was long viewed as an inevitable process of aging, due to an imbalance between osteoclast bone resorbing and osteoblast bone formation function, leading to a negative balance in bone remodeling. This leads to low bone mass and increased bone fragility putting the patient at risk for fracture. While this view still holds, a better understanding disclosed that OP can occur at any age, as a comorbidity or a complication of many diseases and treatments. Differentiation, maturation, and function of osteoclasts and osteoblasts are affected by many factors from different morbidities: endocrine, metabolic, mechanical and inflammatory. Inflammatory diseases are often complicated by a generalized bone loss that subsequently leads to OP. Factors such as glucocorticoid treatment, immobilization, malnutrition, and insufficient intake of vitamin D play a role. However, the inflammatory process itself is involved and the resulting bone loss is termed immune-mediated bone loss. Experiments on animals and on humans, in addition to clinical studies, shed light on the role of inflammation in OP.
After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
PURPOSE:To provide the subject compound having excellent stability to oxidation and solubility in water and useful as a raw material for pharmaceuticals. CONSTITUTION:The subject compound can be produced by adding a catecholamine derivative of formula [R<1> is H or OH; R<2> and R<3> are H, 1-10C alkyl or (substituted) aralkyl] (e.g. epinephrine) to an aqueous solution or suspension of a cyclodextrin (e.g. beta-cyclodextrin). The catecholamine derivative and the cyclodextrin are used at a molar ratio of 1:(1-10). It can be used in the form of eye drop, injection, external preparation, etc., to enable the administration of catecholamine derivative in the form of free base. Catecholamine derivative is a medicine having sympathetic stimulation action and useful as a vasoconstrictor, hemostat, cardiotonic, treating agent for bronchial asthma, mydriatic, etc.
Methods of application of Schisandrin B in the preparation of anticancer medications, and particularly for the preparation of medications for the treatment of multidrug resistant (MDR) cancer. The compound of Schisandrin B effectively reverses MDR cancer in combination with other anticancer chemotherapeutic agents. Schisandrin B reverses MDR cancer by inhibiting the drug efflux activity of P-glycoprotein, indicating its significance in clinical applications. Although it is of low toxicity, Schisandrin B is cytotoxic to human cancer cells, revealing its application in cancer chemotherapy. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
Disclosed are oligomers that bind Ku protein. These oligomers are useful for inhibiting activation of DNA-PK, treating certain forms of autoimmune disease, detection and purification of Ku protein, and identification of proteins that interact with Ku protein. Preferably, the oligomers are composed of nucleotides, nucleotide analogs, or a combination. Most preferably, the oligomers are composed of ribonucleotides. Also disclosed is a method of inhibiting DNA repair, a method of identifying cellular proteins that interact with Ku protein, and a method of treating autoimmune disease in patients with anti-Ku antibodies. The disclosed oligomers can have several preferred features, either alone or in combination, in addition to Ku binding. One such feature, referred to herein as inhibition activity, is inhibition of DNA-PK kinase activity. Another preferred feature, referred to herein as aptamer motifs, is the presence of one or more of the base sequences GCUUUCCCANNNAC, A(A/C)AUGA, and AACUUCGA. These sequences—referred to herein as aptamer motif 1, aptamer motif 2, and aptamer motif 3, respectively—are associated with Ku binding capability. Another preferred feature, referred to herein as aptamer structure, is the presence of a structure similar to the structure shown in FIG. 6A. This structure has the general formula 5′-A-B-C-D-C′-E-A′-3′, where A, B, C, D, C′, E, and A′ are components of the oligomer. In this structure, A and A′ interact to form a stem structure, C and C′ interact to form a stem structure, B and E make up a bulge region, and D is either a bulge or a loop. FIG. 6A depicts component D as a loop. Each of these preferred features (inhibition activity, aptamer motif, and aptamer structure) can be used either alone or in combination with one or both of the other characteristics.
The invention discloses a kind of preparation methods of Lepista mucla (Bull.:Fr.) Cooke water-soluble polysaccharide, this method is directed to the extraction purification of Lepista mucla (Bull.:Fr.) Cooke water-soluble polysaccharide, Thick many candies are tentatively extracted under specific process conditions using water extraction and alcohol precipitation method, and decoloration purifying is carried out using industrialized macroporous adsorption resin chromatography method is easy to, obtain the Lepista mucla (Bull.:Fr.) Cooke water-soluble polysaccharide of high-purity.This method has the characteristics that easy to operate, operating condition is mild, low energy consumption, highly-safe, not destroy polysaccharide component, the yield of polysaccharide high.And it prepares gained and is the Lepista mucla (Bull.:Fr.) Cooke water-soluble polysaccharide of two kinds of new constructions, to further increase the utility value of Lepista mucla (Bull.:Fr.) Cooke, established production basis for the development and application of Lepista mucla (Bull.:Fr.) Cooke polysaccharide.
The invention discloses a fish aeromonas veronii attenuated vaccine strain and application thereof. The aeromonas veronii attenuated vaccine strain is named as FS12001, and is preserved in China center for type culture collection (CCTCC NO) of university of Wuhan in Wuhan, hubei province for 7 days in 3 months of 2023: m2023260. The genome of the attenuated vaccine strain has the size of 4,711,745bp and the GC content of 58.45 percent; has 4,128 coding protein genes, 128 transfer RNA genes and 31 ribosome RNA genes; has 4 CRISPR sequences, 4 gene islands, 4 prophages, 4 gene clusters, 4 promoters and 4 paralogues. Rabbit antisera can produce good specific agglutination with different sources of Aeromonas veronii strains. The attenuated live vaccine and the inactivated vaccine have high safety to freshwater fish, and can effectively prevent bacterial septicemia caused by aeromonas veronii. Has positive effects of reducing the use of antibiotic medicines in preventing and treating bacterial septicemia and guaranteeing the quality safety of aquatic products.
The initial study visit will occur in-person two weeks after discharge from the hospital. Participants will meet with a member of the study staff (the study "trainer") and complete self-report questionnaires assessing health behavior adherence and mental and physical health. Then, participants will be randomized to receive the positive psychology + motivational interviewing or the motivational interviewing health education interventions. A study interventionist will provide a treatment manual specific to their condition, review the rationale for the initial exercise, and assign the first exercise. If the participant is in the positive psychology + motivational interviewing condition, the trainer will explain the rationale for both the positive psychology and goal-setting portions of the program, and will be assigned the first exercise. Similarly, if the participant is randomized into the motivational interviewing health education program, the interventionist will introduce them to the program and assign the first exercise. Participants in both groups will then be given an accelerometer, which they will be asked to wear for 7 days to ensure that they are comfortable with the device and that useable data can be obtained from the participant. Participants in both groups will then complete twelve 30-minute weekly phone sessions with a study trainer. The phone sessions primarily will include a review of the prior week's session content and a discussion of the rationale and assignment of the next week's exercise/assignment. Upon the completion of these calls, and again at a final follow-up timepoint at 24 weeks, a blinded member of the study staff will call participants to administer self-report outcome measures. Participants will also be asked to wear an accelerometer at each of these follow-up timepoints as an objective measure of physical activity, which they will return by mail to the study staff.
There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
Participants who completed Study Period 1 received JOTROL (resveratrol) 500 (5\*100) mg (Treatment B), gelcap, orally, once on Day 1 in fasted conditions in Study Period 2. A 14 days washout period was maintained in study period 1 and 2.
Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
<P>PROBLEM TO BE SOLVED: To provide an excellent technique for lowering a blood glucose level.  <P>SOLUTION: It was obtained as a new knowledge that the joint use of a lactic acid bacteria fermentation product of a balsam pear and a magnesium salt helps lower a blood glucose level. Consequently, a saccachrometabilism improver and/or a visceral fat reducing agent contains the lactic acid bacteria fermentation product and a magnesium salt (preferably a magnesium oxide). Furthermore, preferably the saccharometabolism improving agent and/or the visceral fat reducing agent is mixed with a mulberry leave extract. As lactic acid bacteria, a lactobacillus pentosus is suitable.  <P>COPYRIGHT: (C)2009,JPO&INPIT
OBJECTIVES: Allergic rhinitis (AR) is a complex disorder with variable pathogenesis. Increasing evidence suggests that the LRRC8A is involved in maintaining cellular stability, regulating immune cell activation and function, and playing significant roles in inflammation. However, the involvement of LRRC8A in AR inflammation and its underlying mechanisms remain unclear.
METHODS: LRRC8A expression in AR patients, confirmed by qRT-PCR and Western blotting, was analyzed to investigate its relationship with the clinical characteristics of AR patients. In vitro, IL-13 stimulated HNEpCs to establish a Th2 inflammation model, with subsequent LRRC8A knockout or overexpression. NOX1/NOX4 inhibitor (GKT137831) and chloride channel inhibitor (DCPIB) were utilized to investigate AR development mechanisms during LRRC8A overexpression. An OVA-induced AR model with nasal mucosa LRRC8A knockdown confirmed LRRC8A's regulatory role in AR inflammation.
RESULTS: LRRC8A mRNA and protein levels were significantly elevated in AR patients, positively correlating with NADPH oxidase subunits and Th2 inflammatory markers. In vitro, IL-13 stimulation of HNEpCs resulted in upregulation of LRRC8A and increased expression of NOX1, NOX4, and p22phox, along with mitochondrial dysfunction and NF-κB pathway activation. The knockout of LRRC8A reversed these effects. In nasal mucosal epithelial cells, DCPIB and GKT137831 completely blocked mitochondrial dysfunction caused by the overexpression of LRRC8A, which led to up-regulation of NOX1, NOX4, and p22phox. In vivo, knocking down LRRC8A reduced eosinophil infiltration, downregulated the expression of NOX1, NOX4, p22phox IL-4, IL-5, and IL-13, and decreased NF-κB pathway activation.
CONCLUSION: LRRC8A drives the upregulation of NOX1, NOX4, and p22phox, leading to ROS overproduction and mitochondrial dysfunction. It also activates NF-κB, ultimately leading to nasal mucosal epithelial inflammation. LRRC8A may be a potential target for the treatment of AR.
Currently, the diagnosis of delirium is solely based on clinical observation, lacking objective diagnostic tools, and the regulatory networks and pathological mechanisms behind it are not yet fully understood. Exosomes have garnered considerable interest as potential biomarkers for a variety of illnesses. This research aimed to delineate both the proteomic and metabolomic landscapes inherent to exosomes, assessing their diagnostic utility in postoperative delirium (POD) and understanding the underlying pathophysiological frameworks. Integrated analyses of proteomics and metabolomics were conducted on exosomes derived from plasma of individuals from both the non-postoperative delirium (NPOD) control group and the POD group. Subsequently, the study utilized the Connectivity Map (CMap) methodology for the identification of promising small-molecule drugs and carried out molecular docking assessments to explore the binding affinities with the enzyme MMP9 of these identified molecules. We identified significant differences in exosomal metabolites and proteins between the POD and control groups, highlighting pathways related to neuroinflammation and blood-brain barrier (BBB) integrity. Our CMap analysis identified potential small-molecule therapeutics, and molecular docking studies revealed two compounds with high affinity to MMP9, suggesting a new therapeutic avenue for POD. This study highlights MMP9, TLR2, ICAM1, S100B, and glutamate as key biomarkers in the pathophysiology of POD, emphasizing the roles of neuroinflammation and BBB integrity. Notably, molecular docking suggests mirin and orantinib as potential inhibitors targeting MMP9, providing new therapeutic avenues. The findings broaden our understanding of POD mechanisms and suggest targeted strategies for its management, reinforcing the importance of multidimensional biomarker analysis and molecular targeting in POD intervention.